Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (noted as Cocrystal Pharma, Inc. in metadata) on April 12, 2013, with the latest event date of April 18, 2013. The filing reports unregistered sales of equity securities to accredited investors under Section 4(2) and Regulation D of the Securities Act of 1933.
Key Financial Metrics
The filing details a capital raise consisting of two tranches of Unit sales:
- Total Units Sold: 3,200,000 Units (2,000,000 on April 12 and 1,200,000 on April 18).
- Gross Proceeds: $800,000 ($500,000 from the first tranche and $300,000 from the second).
- Price Per Unit: $0.25.
- Placement Agent Fees: $26,500 paid in cash, plus a warrant to purchase 16,000 shares.
The filing text does not provide clear values for revenue, profit, operating cash flow, margins, total debt, or liquidity ratios, as this is a current report focused on a specific transaction rather than a periodic financial statement.
Material Changes
The primary material change is the increase in outstanding equity and potential dilution resulting from the sale of 3,200,000 Units. Each Unit consists of one share of common stock and a five-year warrant to purchase 50% of the number of shares purchased (1,600,000 total warrants) at an exercise price of $0.50 per share.
Outlook, Risks, and Unusual Items
Warrant Terms: Warrants may be exercised on a cashless basis if no effective registration statement exists for the underlying shares. There are beneficial ownership limitations preventing exercise if the holder would own more than 4.99% of outstanding common stock, though this can be increased to 9.99% with 61 days' notice.
Risks: The offering relies on exemptions from registration; the filing notes that the summary is not complete and refers to the Subscription Agreement and Warrant exhibits for full terms.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the status of the registration statement for the resale of shares underlying the warrants.
- Review the full text of the Subscription Agreement (Exhibit 10.1) and Warrant (Exhibit 10.2) for additional covenants or restrictions.
- Assess the company's cash position relative to the $800,000 gross proceeds and $26,500 in fees to determine runway extension.